Does the media favor CYRX or TNGX?

In the previous week, Tango Therapeutics had 14 more articles in the media than CryoPort. MarketBeat recorded 23 mentions for Tango Therapeutics and 9 mentions for CryoPort. Tango Therapeutics' average media sentiment score of 0.10 beat CryoPort's score of -0.08 indicating that Tango Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tango Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Neutral

Which has higher valuation and earnings, CYRX or TLX?

CryoPort has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.18 $78.30M $1.35 10.83 Telix Pharmaceuticals $803.79M 4.04 -$7.12M N/A N/A

Does the media favor CYRX or TLX?

In the previous week, CryoPort had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 9 mentions for CryoPort and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.50 beat CryoPort's score of -0.08 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CYRX or RCUS?

In the previous week, Arcus Biosciences had 1 more articles in the media than CryoPort. MarketBeat recorded 10 mentions for Arcus Biosciences and 9 mentions for CryoPort. Arcus Biosciences' average media sentiment score of 0.75 beat CryoPort's score of -0.08 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, RLAY or CYRX?

CryoPort has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Relay Therapeutics $15.35M 184.85 -$276.48M -$1.57 N/A CryoPort $176.18M 4.18 $78.30M $1.35 10.83

Does the media prefer RLAY or CYRX?

In the previous week, CryoPort had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 9 mentions for CryoPort and 4 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.10 beat CryoPort's score of -0.08 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

CryoPort (CYRX) Competitors

$14.62 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$14.79 +0.17 (+1.16%)

As of 06/12/2026 06:40 PM Eastern

Compare

CYRX vs. TNGX, TLX, RCUS, DNLI, and RLAY

Should you buy CryoPort stock or one of its competitors? MarketBeat compares CryoPort with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CryoPort include Tango Therapeutics (TNGX), Telix Pharmaceuticals (TLX), Arcus Biosciences (RCUS), Denali Therapeutics (DNLI), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry.

How does CryoPort compare to Tango Therapeutics?

CryoPort (NASDAQ:CYRX) and Tango Therapeutics (NASDAQ:TNGX) are both pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 79.0% of Tango Therapeutics shares are owned by institutional investors. 10.1% of CryoPort shares are owned by insiders. Comparatively, 6.5% of Tango Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CryoPort presently has a consensus target price of $15.11, suggesting a potential upside of 3.36%. Tango Therapeutics has a consensus target price of $38.42, suggesting a potential upside of 24.17%. Given Tango Therapeutics' higher probable upside, analysts plainly believe Tango Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

CryoPort has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market. Comparatively, Tango Therapeutics has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

In the previous week, Tango Therapeutics had 14 more articles in the media than CryoPort. MarketBeat recorded 23 mentions for Tango Therapeutics and 9 mentions for CryoPort. Tango Therapeutics' average media sentiment score of 0.10 beat CryoPort's score of -0.08 indicating that Tango Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tango Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Neutral

CryoPort has higher revenue and earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.18	$78.30M	$1.35	10.83
Tango Therapeutics	$62.38M	71.75	-$101.59M	-$0.83	N/A

CryoPort has a net margin of 41.57% compared to Tango Therapeutics' net margin of -151.15%. CryoPort's return on equity of -7.92% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Tango Therapeutics	-151.15%	-41.54%	-33.44%

Summary

CryoPort beats Tango Therapeutics on 11 of the 16 factors compared between the two stocks.

How does CryoPort compare to Telix Pharmaceuticals?

CryoPort (NASDAQ:CYRX) and Telix Pharmaceuticals (NASDAQ:TLX) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

CryoPort currently has a consensus target price of $15.11, suggesting a potential upside of 3.36%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 120.97%. Given Telix Pharmaceuticals' higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

CryoPort has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.18	$78.30M	$1.35	10.83
Telix Pharmaceuticals	$803.79M	4.04	-$7.12M	N/A	N/A

In the previous week, CryoPort had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 9 mentions for CryoPort and 2 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.50 beat CryoPort's score of -0.08 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

92.9% of CryoPort shares are owned by institutional investors. 10.1% of CryoPort shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CryoPort has a net margin of 41.57% compared to Telix Pharmaceuticals' net margin of 0.00%. Telix Pharmaceuticals' return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Telix Pharmaceuticals	N/A	N/A	N/A

CryoPort has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market.

Summary

CryoPort beats Telix Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does CryoPort compare to Arcus Biosciences?

CryoPort (NASDAQ:CYRX) and Arcus Biosciences (NYSE:RCUS) are both pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Arcus Biosciences had 1 more articles in the media than CryoPort. MarketBeat recorded 10 mentions for Arcus Biosciences and 9 mentions for CryoPort. Arcus Biosciences' average media sentiment score of 0.75 beat CryoPort's score of -0.08 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

CryoPort presently has a consensus price target of $15.11, suggesting a potential upside of 3.36%. Arcus Biosciences has a consensus price target of $35.10, suggesting a potential upside of 47.17%. Given Arcus Biosciences' higher possible upside, analysts clearly believe Arcus Biosciences is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

CryoPort has a net margin of 41.57% compared to Arcus Biosciences' net margin of -156.36%. CryoPort's return on equity of -7.92% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

CryoPort has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.18	$78.30M	$1.35	10.83
Arcus Biosciences	$247M	12.14	-$353M	-$3.18	N/A

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are owned by institutional investors. 10.1% of CryoPort shares are owned by insiders. Comparatively, 9.6% of Arcus Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CryoPort beats Arcus Biosciences on 10 of the 15 factors compared between the two stocks.

How does CryoPort compare to Denali Therapeutics?

CryoPort (NASDAQ:CYRX) and Denali Therapeutics (NASDAQ:DNLI) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

CryoPort has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the broader market.

In the previous week, CryoPort had 8 more articles in the media than Denali Therapeutics. MarketBeat recorded 9 mentions for CryoPort and 1 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.87 beat CryoPort's score of -0.08 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CryoPort	Neutral
Denali Therapeutics	Very Positive

CryoPort has a net margin of 41.57% compared to Denali Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Denali Therapeutics	N/A	-52.20%	-43.86%

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are owned by institutional investors. 10.1% of CryoPort shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CryoPort has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.18	$78.30M	$1.35	10.83
Denali Therapeutics	$330.53M	10.40	-$512.54M	-$2.88	N/A

CryoPort presently has a consensus target price of $15.11, suggesting a potential upside of 3.36%. Denali Therapeutics has a consensus target price of $34.25, suggesting a potential upside of 58.13%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Summary

Denali Therapeutics beats CryoPort on 9 of the 17 factors compared between the two stocks.

How does CryoPort compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and CryoPort (NASDAQ:CYRX) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Relay Therapeutics presently has a consensus target price of $23.30, suggesting a potential upside of 57.33%. CryoPort has a consensus target price of $15.11, suggesting a potential upside of 3.36%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Relay Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

CryoPort has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$15.35M	184.85	-$276.48M	-$1.57	N/A
CryoPort	$176.18M	4.18	$78.30M	$1.35	10.83

In the previous week, CryoPort had 5 more articles in the media than Relay Therapeutics. MarketBeat recorded 9 mentions for CryoPort and 4 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.10 beat CryoPort's score of -0.08 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 10.1% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Relay Therapeutics has a beta of 1.75, indicating that its share price is 75% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

CryoPort has a net margin of 41.57% compared to Relay Therapeutics' net margin of 0.00%. CryoPort's return on equity of -7.92% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
CryoPort	41.57%	-7.92%	-4.79%

Summary

CryoPort beats Relay Therapeutics on 10 of the 16 factors compared between the two stocks.

Get CryoPort News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CYRX vs. The Competition

Export

Metric	CryoPort	TRANS Industry	Transportation Sector	NASDAQ Exchange
Market Cap	$736.85M	$7.32B	$8.81B	$12.07B
Dividend Yield	N/A	2.35%	983.11%	5.67%
P/E Ratio	10.83	29.40	25.54	24.42
Price / Sales	4.18	2.20	6.26	109.94
Price / Cash	N/A	10.11	8.66	37.92
Price / Book	1.59	2.56	2.26	6.83
Net Income	$78.30M	$242.75M	$535.59M	$337.67M
7 Day Performance	-5.56%	1.62%	1.67%	1.17%
1 Month Performance	11.26%	11.31%	8.95%	3.16%
1 Year Performance	119.19%	5.41%	35.45%	30.58%

CryoPort Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CYRX CryoPort	2.4215 of 5 stars	$14.62 flat	$15.11 +3.4%	+119.2%	$736.85M	$176.18M	10.83	1,186	Insider Trade
TNGX Tango Therapeutics	2.354 of 5 stars	$21.47 -0.1%	$32.27 +50.3%	+559.7%	$3.11B	$62.38M	N/A	90	Gap Down
TLX Telix Pharmaceuticals	4.4896 of 5 stars	$8.77 -4.3%	$21.13 +140.9%	-40.6%	$3.11B	$803.79M	N/A	1,184	High Trading Volume
RCUS Arcus Biosciences	2.9246 of 5 stars	$23.88 -2.4%	$33.89 +41.9%	+157.8%	$3.08B	$247M	N/A	500
DNLI Denali Therapeutics	3.2157 of 5 stars	$19.66 +1.6%	$34.25 +74.2%	+48.9%	$3.07B	$330.53M	N/A	430	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CYRX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CryoPort (CYRX) Competitors

CYRX vs. TNGX, TLX, RCUS, DNLI, and RLAY

How does CryoPort compare to Tango Therapeutics?

Summary

How does CryoPort compare to Telix Pharmaceuticals?

Summary

How does CryoPort compare to Arcus Biosciences?

Summary

How does CryoPort compare to Denali Therapeutics?

Summary

How does CryoPort compare to Relay Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CryoPort (CYRX) Competitors

CYRX vs. TNGX, TLX, RCUS, DNLI, and RLAY

How does CryoPort compare to Tango Therapeutics?

Do insiders and institutionals hold more shares of CYRX or TNGX?

Do analysts rate CYRX or TNGX?

Which has more risk & volatility, CYRX or TNGX?

Does the media favor CYRX or TNGX?

Which has higher earnings & valuation, CYRX or TNGX?

Is CYRX or TNGX more profitable?

Summary

How does CryoPort compare to Telix Pharmaceuticals?

Do analysts recommend CYRX or TLX?

Which has higher valuation and earnings, CYRX or TLX?

Does the media favor CYRX or TLX?

Do institutionals & insiders have more ownership in CYRX or TLX?

Is CYRX or TLX more profitable?

Which has more volatility and risk, CYRX or TLX?

Summary

How does CryoPort compare to Arcus Biosciences?

Does the media favor CYRX or RCUS?

Which has more risk & volatility, CYRX or RCUS?

Do analysts prefer CYRX or RCUS?

Is CYRX or RCUS more profitable?

Which has stronger earnings & valuation, CYRX or RCUS?

Do institutionals and insiders have more ownership in CYRX or RCUS?

Summary

How does CryoPort compare to Denali Therapeutics?

Which has more risk & volatility, CYRX or DNLI?

Does the media refer more to CYRX or DNLI?

Is CYRX or DNLI more profitable?

Do insiders and institutionals hold more shares of CYRX or DNLI?

Which has better earnings & valuation, CYRX or DNLI?

Do analysts rate CYRX or DNLI?

Summary

How does CryoPort compare to Relay Therapeutics?

Do analysts prefer RLAY or CYRX?

Which has preferable valuation & earnings, RLAY or CYRX?

Does the media prefer RLAY or CYRX?

Do institutionals & insiders have more ownership in RLAY or CYRX?

Which has more risk and volatility, RLAY or CYRX?

Is RLAY or CYRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CYRX vs. The Competition

CryoPort Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools